CD1530 is a selective retinoic acid receptor (RARγ) agonist (Kds = 150, 1,500, and 2,750 nM for RARγ, RARβ, and RARα receptors, respectively). It demonstrates transcriptional activity at RARγ with an AC50 value of 1.8 nM. It has been used in combination with bexarotene , a retinoid X receptor agonist, to inhibit oral carcinogenesis induced by the carcinogen 4-nitroquinoline 1-oxide in a mouse model of human oral-cavity and esophageal squamous-cell carcinoma.
